ISPE Regulatory Update: Key Changes from EMA and FDA in February 2026 – AI, Reform, and Practical Compliance

February 2026 marks a pivotal moment in pharmaceutical regulation, with simultaneous advances in artificial intelligence governance, landmark EU legislative reform, and targeted deadline-driven updates for veterinary GMP, cell and gene therapies, and e-labelling. The underlying economic logic is clear: regulators are pursuing harmonization to reduce R&D friction while creating local compliance complexities that manufacturers must navigate with precision.

---

Introduction: The Regulatory Momentum of February 2026

The month’s announcements—spanning EMA-FDA common principles for AI, a political agreement on EU pharmaceutical legislation reform, binding veterinary GMP deadlines, French e-labelling pilots, and FDA flexibility updates—reveal a deliberate dual strategy. On one hand, agencies incentivize innovation by streamlining approval pathways for biologics and AI-enabled tools. On the other, they tighten operational compliance through standardized protocols (PACMPs, Q&A updates) and digitalization mandates (e-labelling).

This article dissects the hidden economic logic: harmonization lowers cross-border barriers but introduces local variances—most notably the French e-notice pilot diverging from EU-wide e-labelling norms. Manufacturers that map these changes to their cost structures and supply chain digitalization agendas will gain a strategic advantage before the July 2026 veterinary GMP deadline and beyond.

---

EMA and FDA: Common Principles for AI in Medicine Development – A Genuine Step Toward Global Standards?

In February 2026, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) jointly published a set of common principles for the use of artificial intelligence throughout the medicine development lifecycle. The principles address AI validation, transparency, lifecycle management, and data governance—areas that have previously been governed by divergent national guidance.

While the document is non-binding, its strategic significance is substantial. For the first time, the two largest pharmaceutical regulatory bodies have aligned their expectations on AI-driven clinical trial design, real-world evidence generation, and post-market surveillance. The practical consequence for manufacturers is a reduced risk of parallel submission requirements across the Atlantic. Companies developing AI-based algorithms for drug development or AI-enabled medical devices can now reference a single set of high-level expectations during early-stage planning.

The FDA separately issued a request for public comment (Docket No. FDA-2025-N-4203) on measuring AI-enabled medical device performance in real-world settings, published in October 2025 (Source: FDA request for comment). This aligns with the joint principles’ emphasis on lifecycle performance monitoring. Manufacturers should already be mapping their internal AI governance frameworks to these principles to avoid future submission delays—especially for combination products where AI components shape safety or efficacy profiles.

Economic inference: The convergence reduces the cost of regulatory duplication for global developers but demands upfront investment in documentation that meets both EMA and FDA benchmarks. Companies that delay adoption risk increased review cycles.

---

EU Pharmaceutical Legislation Reform: Political Agreement Reached – What Comes Next?

EMA formally welcomed the political agreement reached by the European Commission, the European Parliament, and the Council of the European Union on the comprehensive reform of the EU pharmaceutical legislation (Directive 192 and Regulation 193). The package was published in draft form in October 2025; the February 2026 political agreement sets the stage for final adoption and publication later in 2026 (Source: EMA statement on political agreement).

The economic logic of the reform balances two conflicting objectives: incentivizing innovation through extended data exclusivity and orphan drug provisions, while improving access and affordability. Manufacturers face a tension between protecting long-term exclusivity periods and accepting earlier market entry of generics and biosimilars. The exact duration of these provisions will only be confirmed upon final publication, but scenario planning should begin now.

Key timeline variables: once published, the legislation will enter into force 20 days later, with most provisions requiring transposition by member states within a specified period (likely 18–24 months). Companies should model revenue projections under different exclusivity scenarios and prepare adaptive market access strategies.

---

Veterinary GMP Compliance: The July 2026 Deadline Is Firm

Two Commission Implementing Regulations set binding requirements for veterinary medicinal products and their active substances:

• Commission Implementing Regulation (EU) 2025/2091 on GMP for veterinary medicinal products, applicable as of 16 July 2026.
• Commission Implementing Regulation (EU) 2025/2154 on GMP for active substances used as starting materials in veterinary medicinal products, also applicable as of 16 July 2026.

Both regulations were published in November 2025 (Source: Official Journal of the EU). The transition period is less than five months from the time of this article. Manufacturers of veterinary products—including those producing in third countries for EU export—must ensure their quality management systems and facility inspections comply with the new requirements.

Practical implications: facilities that previously operated under human GMP standards may already meet the baseline, but veterinary-specific provisions (e.g., dedicated manufacturing for certain active substances, cross-contamination prevention for feed additive combinations) require verification. Regulatory authorities will begin pre- and post-market inspections shortly after applicability.

Strategic note: The veterinary GMP regulations align with the broader EU trend toward tightening supply chain oversight for all medicinal products. Manufacturers should treat this deadline as non-negotiable and conduct gap analyses immediately.

---

Post-Approval Change Management: PACMPs Effective January 2026

The EMA revised its Q&A on post-approval change management protocols (PACMPs), with the updated version published in December 2025 and effective as of 15 January 2026 (Source: EMA Q&A on PACMPs). PACMPs allow manufacturers to pre-approve certain types of variations, reducing the time and cost of implementing post-approval changes.

The revision clarifies submission procedures, data requirements, and the scope of variations eligible for PACMP use. For manufacturers, the adoption of PACMPs can cut regulatory review timelines by 6–12 months for repetitive changes and reduce the administrative burden of multiple variations.

Economic logic: Regulators are trading short-term oversight for long-term efficiency. Companies that invest in developing robust PACMPs for their high-volume products will see faster time-to-market for improvements and cost savings from streamlined dossier updates. The risk lies in poorly designed protocols that trigger rework or inspection findings.

---

E-Labelling and Digital Innovation: French Pilot Diverges from EU-Wide Norms

France’s National Agency for the Safety of Medicines and Health Products (ANSM) launched a 2-year pilot for e-notice (e-labelling) covering approximately 420 hospital-only products that no longer require paper leaflets, and 170 pharmacy-dispensed products that must maintain both digital and paper systems (Source: ANSM pilot announcement, as referenced in ISPE data).

This pilot creates a local compliance divergence from the EU-wide framework, which has not yet adopted mandatory e-labelling for human medicines. Manufacturers supplying the French market must adapt their packaging and leaflet workflows—maintaining dual systems for pharmacy products while eliminating paper for hospital-only items.

The pilot carries implications for larger digital transformation strategies. If successful, it could accelerate EU-level legislation on e-labelling, potentially harmonizing formats and data carriers. For now, companies should monitor the pilot’s outcomes and prepare for scalable digital leaflet management systems that can handle country-specific requirements.

---

Cell and Gene Therapies: FDA Increases Flexibility

The FDA announced increased flexibility regarding certain requirements for cell and gene therapies in February 2026 (Source: FDA announcement, as referenced in ISPE data). While specific details were not provided in the raw data, this move aligns with global trends to expedite access to advanced therapies that treat rare or life-threatening conditions.

For manufacturers, this means potential reductions in preclinical data requirements, expedited clinical trial designs, or streamlined CMC standards for well-characterized products. The economic impact is significant: lower development costs and faster time-to-approval offset the high R&D expenditure typical of cell and gene therapy programs. However, flexibility does not imply lower quality standards—manufacturers must still demonstrate safety and efficacy, and post-market surveillance obligations remain robust.

---

Other Agency Actions: Swissmedic, FDA Medical Gases, and Guidance Updates

Swissmedic approved a redundancy scheme for announced headcount reduction in February 2026 (Source: Swissmedic communication). While this does not directly alter regulatory requirements, it signals potential delays in review timelines and inspection scheduling. Companies with submissions pending at Swissmedic should proactively communicate with the agency and plan for extended review periods.

The FDA published draft guidance on Quality Management System Information for Certain Premarket Submission Reviews, as well as Filing Checklists and Good Review Practice regarding Refuse to File for new drugs and generics (Source: FDA publications listed in ISPE data). These guidance documents standardize submission expectations, reducing the risk of refusal due to incomplete information. Manufacturers should update their submission templates to align with the new checklists.

For medical gases, the FDA reiterated that under section 501(a)(2)(B) of the FD&C Act, a drug—including a medical gas—is deemed adulterated if its manufacturing methods or controls do not conform to CGMP (Source: FDA guidance on medical gases). Comments were due 30 January 2026. This reaffirms that medical gas producers, often operating under specialized exemption histories, must now fully comply with CGMP standards.

---

Outlook and Strategic Recommendations

The February 2026 regulatory landscape is defined by converging timelines and diverging local requirements. Manufacturers face four concrete near-term actions:

• Map AI governance frameworks to the EMA-FDA common principles before mid-2026, especially for products incorporating AI in development or clinical use.
• Complete veterinary GMP gap analyses against Regulations (EU) 2025/2091 and 2025/2154 before June 2026 to allow time for remediation.
• Adopt PACMPs for high-change products to capitalize on the January 2026 effective date and reduce future variation review burdens.
• Monitor the French e-labelling pilot and prepare scalable digital leaflet systems that can accommodate both hospital-only and pharmacy product requirements.

The dual strategy of innovation push and compliance stream will continue: expect further harmonization of AI guidelines, EU pharmaceutical legislation finalization by Q4 2026, and potential expansion of e-labelling pilots to other member states. Companies that treat these updates as strategic inputs—rather than merely operational obligations—will reduce regulatory risk and improve time-to-value for new products.